312.02
0.62 (0.20%)
| Penutupan Terdahulu | 311.40 |
| Buka | 313.19 |
| Jumlah Dagangan | 410,796 |
| Purata Dagangan (3B) | 447,211 |
| Modal Pasaran | 12,219,381,760 |
| Harga / Pendapatan (P/E TTM) | 74.11 |
| Harga / Pendapatan (P/E Ke hadapan) | 68.97 |
| Harga / Jualan (P/S) | 10.43 |
| Harga / Buku (P/B) | 10.13 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Keuntungan | 3.41% |
| Margin Operasi (TTM) | 12.45% |
| EPS Cair (TTM) | 1.09 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 16.30% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 256.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.19% |
| Nisbah Semasa (MRQ) | 6.30 |
| Aliran Tunai Operasi (OCF TTM) | 179.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 135.83 M |
| Pulangan Atas Aset (ROA TTM) | 5.82% |
| Pulangan Atas Ekuiti (ROE TTM) | 3.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Penumbra, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.80 |
|
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.64% |
| % Dimiliki oleh Institusi | 91.96% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 388.00 (Needham, 24.35%) | Beli |
| Median | 374.00 (19.86%) | |
| Rendah | 349.00 (BTIG, 11.85%) | Pegang |
| Purata | 372.42 (19.36%) | |
| Jumlah | 3 Beli, 9 Pegang | |
| Harga Purata @ Panggilan | 342.14 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Canaccord Genuity | 20 Jan 2026 | 374.00 (19.86%) | Pegang | 355.44 |
| 17 Dec 2025 | 359.00 (15.06%) | Beli | 309.26 | |
| RBC Capital | 20 Jan 2026 | 374.00 (19.86%) | Pegang | 355.44 |
| BTIG | 16 Jan 2026 | 349.00 (11.85%) | Pegang | 350.78 |
| Baird | 16 Jan 2026 | 374.00 (19.86%) | Pegang | 350.78 |
| Citigroup | 16 Jan 2026 | 374.00 (19.86%) | Pegang | 350.78 |
| 11 Dec 2025 | 350.00 (12.17%) | Beli | 311.40 | |
| Jefferies | 16 Jan 2026 | 374.00 (19.86%) | Pegang | 350.78 |
| Leerink Partners | 16 Jan 2026 | 374.00 (19.86%) | Pegang | 350.78 |
| Truist Securities | 16 Jan 2026 | 374.00 (19.86%) | Pegang | 350.78 |
| 18 Dec 2025 | 370.00 (18.58%) | Beli | 315.35 | |
| Wells Fargo | 15 Jan 2026 | 374.00 (19.86%) | Pegang | 350.49 |
| B of A Securities | 05 Jan 2026 | 370.00 (18.58%) | Beli | 315.00 |
| JP Morgan | 18 Dec 2025 | 370.00 (18.58%) | Beli | 315.35 |
| 06 Nov 2025 | 275.00 (-11.86%) | Pegang | 264.61 | |
| Needham | 17 Dec 2025 | 388.00 (24.35%) | Beli | 309.26 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| NARAYAN SHRUTHI | - | 350.49 | -286 | -100,240 |
| Jumlah Keseluruhan Kuantiti Bersih | -286 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -100,240 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 350.49 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| NARAYAN SHRUTHI | Pegawai | 15 Jan 2026 | Dibuang (-) | 286 | 350.49 | 100,240 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 15 Jan 2026 | Pengumuman | Penumbra, Inc. Provides Preliminary Update on Fourth Quarter and Full Year 2025 Financial Results |
| 15 Jan 2026 | Pengumuman | Boston Scientific announces agreement to acquire Penumbra, Inc. |
| 29 Dec 2025 | Pengumuman | Penumbra, Inc. to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 19 Nov 2025 | Pengumuman | Penumbra, Inc. to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 05 Nov 2025 | Pengumuman | Penumbra, Inc. Reports Third Quarter 2025 Financial Results |
| 03 Nov 2025 | Pengumuman | Latest Data from Landmark STORM-PE Randomized Controlled Trial Demonstrate that CAVT with Anticoagulation Significantly Improves Functional Outcomes for Patients with Pulmonary Embolism |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |